| P2093 | author name string | Rutherford JD | |
| P2860 | cites work | In vitro stimulation of plasminogen activator release from vein walls by adrenaline | Q33837354 |
| | The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina | Q34000264 |
| | Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 |
| | Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor | Q34573519 |
| | Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 |
| | Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis | Q35552418 |
| | Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes | Q37420707 |
| | Prognosis and management after a first myocardial infarction | Q38147342 |
| | Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 |
| | Plasminogen activator inhibitors | Q39592746 |
| | The Role of Endothelium in Cardiovascular Homeostasis and Diseases | Q40393494 |
| | Prospective study of endogenous tissue plasminogen activator and risk of stroke | Q41036094 |
| | Endogenous tissue-type plasminogen activator and risk of myocardial infarction | Q41079493 |
| | Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study) | Q42285969 |
| | Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 |
| | Effects of benazepril, a new ACE inhibitor, in effort angina pectoris | Q43525617 |
| | Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies | Q43950275 |
| | A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators | Q44602168 |
| | Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. | Q45970935 |
| | Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. | Q52057197 |
| | Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. | Q52374689 |
| | Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 |
| | Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris | Q54319505 |
| | Effects of Captopril on the Physical Work Capacity of Normotensive Patients with Stable-Effort Angina pectoris | Q57988067 |
| | Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions | Q67523344 |
| | Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trial with benazepril | Q67696352 |
| | A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1 | Q67983066 |
| | Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris | Q67989768 |
| | The angiotensin-converting enzyme inhibitor in the treatment of angina pectoris | Q68100558 |
| | Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure | Q68194523 |
| | Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma | Q68352987 |
| | Elevation of C-reactive protein in "active" coronary artery disease | Q68696120 |
| | Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina | Q69825820 |
| | Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect | Q69880735 |
| | Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction | Q69901572 |
| | Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction | Q69973450 |
| | Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction | Q70633256 |
| | Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function | Q70743346 |
| | Fibrinogen as a risk factor for stroke and myocardial infarction | Q71438059 |
| | Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators | Q72711428 |
| | Plasma renin activity and ischemic heart disease | Q72857047 |
| P304 | page(s) | 57-66; discussion 66-7 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Transactions of the American Clinical and Climatological Association | Q24056174 |
| P1476 | title | Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action? | |
| P478 | volume | 107 | |